216 related articles for article (PubMed ID: 18385996)
1. Early prediction of response to therapy: the clinical implications in Hodgkin's and non-Hodgkin's lymphoma.
Kostakoglu L
Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1413-20. PubMed ID: 18385996
[No Abstract] [Full Text] [Related]
2. Hodgkin's and non-Hodgkin's lymphomas.
Rademaker J
Radiol Clin North Am; 2007 Jan; 45(1):69-83. PubMed ID: 17157624
[TBL] [Abstract][Full Text] [Related]
3. The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.
Qiu L; Chen Y; Wu J
Hell J Nucl Med; 2013; 16(3):230-6. PubMed ID: 24137577
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: where is the evidence?
Juweid ME
J Nucl Med; 2008 Jan; 49(1):9-12. PubMed ID: 18077522
[No Abstract] [Full Text] [Related]
5. Expert opinions on positron emission tomography and computed tomography imaging in lymphoma.
Delbeke D; Stroobants S; de Kerviler E; Gisselbrecht C; Meignan M; Conti PS
Oncologist; 2009; 14 Suppl 2():30-40. PubMed ID: 19819922
[TBL] [Abstract][Full Text] [Related]
6. [Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in the treatment of Hodgkin's disease and malignant non-Hodgkin's lymphoma].
Bourguet P;
Bull Cancer; 2003 Feb; 90 Spec No():S88-95. PubMed ID: 12739340
[No Abstract] [Full Text] [Related]
7. FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma.
Kasamon YL; Wahl RL
Curr Opin Oncol; 2008 Mar; 20(2):206-19. PubMed ID: 18300772
[TBL] [Abstract][Full Text] [Related]
8. Value of positron emission tomography in diagnosing subcutaneous panniculitis-like T-cell lymphoma.
Bennani-Baiti B; Yadav S; Flynt L; Bennani-Baiti N
J Clin Oncol; 2015 Apr; 33(10):1216-7. PubMed ID: 25691676
[No Abstract] [Full Text] [Related]
9. Evaluation of treatment response in patients with lymphoma using [18F]FDG-PET: differences between non-Hodgkin's lymphoma and Hodgkin's disease.
Spaepen K; Mortelmans L
Q J Nucl Med; 2001 Sep; 45(3):269-73. PubMed ID: 11788819
[TBL] [Abstract][Full Text] [Related]
10. FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin's lymphoma and Hodgkin's disease.
Querellou S; Valette F; Bodet-Milin C; Oudoux A; Carlier T; Harousseau JL; Chatal JF; Couturier O
Ann Hematol; 2006 Nov; 85(11):759-67. PubMed ID: 16871391
[TBL] [Abstract][Full Text] [Related]
11. Diffuse skeletal muscle F-18 fluorodeoxyglucose uptake in advanced primary muscle non-Hodgkin's lymphoma.
Broski SM; Bou-Assaly W; Gross MD; Fig LM
Clin Nucl Med; 2009 Apr; 34(4):251-3. PubMed ID: 19300063
[TBL] [Abstract][Full Text] [Related]
12. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma.
Cheson BD
Radiol Clin North Am; 2008 Mar; 46(2):213-23, vii. PubMed ID: 18619377
[TBL] [Abstract][Full Text] [Related]
13. Prospective study of 18F-FDG PET in pediatric mediastinal lymphoma: a single center experience.
Edeline V; Bonardel G; Brisse H; Foehrenbach H; Pacquement H; Maszelin P; Gaillard JF; Michon J; Neuenschwander S
Leuk Lymphoma; 2007 Apr; 48(4):823-6. PubMed ID: 17454646
[No Abstract] [Full Text] [Related]
14. Do not abandon the bone marrow biopsy yet in diffuse large B-cell lymphoma.
Adams HJ; Kwee TC
J Clin Oncol; 2015 Apr; 33(10):1217. PubMed ID: 25691675
[No Abstract] [Full Text] [Related]
15. Update on Hodgkin lymphoma from a radiologist's perspective.
Levine I; Kalisz K; Smith DA; Tirumani SH; Ramaiya NH; Alessandrino F
Clin Imaging; 2020 Sep; 65():65-77. PubMed ID: 32361412
[TBL] [Abstract][Full Text] [Related]
16. The use of interim (18)F-fluorodeoxyglucose PET to guide therapy in lymphoma.
Araf S; Montoto S
Future Oncol; 2013 Jun; 9(6):807-15. PubMed ID: 23718301
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG-PET/CT findings in a patient with tuberculosis Hodgkin's disease and lupus vulgaris.
Kaya E; Halac M; Sönmezoglu K; Sager S; Uslu I
Hell J Nucl Med; 2009; 12(3):285-6. PubMed ID: 19936348
[No Abstract] [Full Text] [Related]
18. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.
Wirth A; Seymour JF; Hicks RJ; Ware R; Fisher R; Prince M; MacManus MP; Ryan G; Januszewicz H; Wolf M
Am J Med; 2002 Mar; 112(4):262-8. PubMed ID: 11893364
[TBL] [Abstract][Full Text] [Related]
19. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M
J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482
[TBL] [Abstract][Full Text] [Related]
20. Role of WB-MR/DWIBS compared to (18)F-FDG PET/CT in the therapy response assessment of lymphoma.
Maggialetti N; Ferrari C; Minoia C; Asabella AN; Ficco M; Loseto G; De Tullio G; de Fazio V; Calabrese A; Guarini A; Rubini G; Brunese L
Radiol Med; 2016 Feb; 121(2):132-43. PubMed ID: 26349573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
